How Much Does Farxiga (Dapagliflozin) Cost in Montana in 2026?

Montana Retail Pricing: What You'll Pay Without Insurance

The average cash-pay price for brand-name Farxiga across Montana retail pharmacies sits at $620 per month in 2026. That figure holds relatively stable whether you fill at Albertsons in Billings, a Walmart pharmacy in Great Falls, or an independent in Missoula. No generic dapagliflozin is available in the U.S. market yet, as AstraZeneca's patent exclusivity extends through the mid-2020s.

This $620 figure represents the wholesale acquisition cost passed through to consumers without insurance negotiation. Montana's smaller population (approximately 1.1 million residents) means fewer high-volume discount pharmacies compared to states like Texas or California. Price variation between pharmacies within Montana rarely exceeds $30 in either direction.

For context, dapagliflozin 10 mg proved its clinical value in DAPA-HF (N=4,744), reducing the composite endpoint of worsening heart failure or cardiovascular death by 26% versus placebo (HR 0.74; 95% CI 0.65-0.85; P<0.001). That trial enrolled patients regardless of diabetes status, broadening the drug's utility well beyond glycemic control [1].

The FDA label for dapagliflozin now carries three distinct indications: type 2 diabetes mellitus, heart failure with reduced ejection fraction, and chronic kidney disease with albuminuria [2]. Each indication carries the same dose (10 mg daily) and the same price.

Montana Medicaid: Why Farxiga Isn't Covered and What to Do

Montana Medicaid does not cover Farxiga as of 2026. The state's preferred drug list (PDL) excludes dapagliflozin entirely from the SGLT2 inhibitor class, directing beneficiaries toward older, less expensive antidiabetic options.

This coverage gap affects roughly 275,000 Montanans enrolled in the state's Medicaid expansion program. The exclusion appears driven by budget constraints rather than clinical skepticism. Montana's Medicaid drug spending operates under a tighter per-member-per-month ceiling than wealthier states.

Patients on Montana Medicaid who need an SGLT2 inhibitor have limited formal options. A prior authorization request citing heart failure or CKD (rather than diabetes alone) may occasionally succeed, but approval rates remain low. The DAPA-CKD trial (N=4,304) demonstrated a 39% reduction in sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death (HR 0.61; 95% CI 0.51-0.72) [3]. Citing this evidence in a prior authorization letter strengthens the clinical necessity argument.

Alternative pathways for Medicaid patients include: (1) the AstraZeneca patient assistance program for those meeting income criteria, (2) compounded dapagliflozin through a 503A pharmacy (discussed below), or (3) appealing the Medicaid denial with specialist documentation from a cardiologist or nephrologist.

Commercial Insurance Coverage in Montana

Most commercial insurance plans available in Montana do cover Farxiga, though placement varies between Tier 2 (preferred brand) and Tier 3 (non-preferred brand). Blue Cross Blue Shield of Montana, Pacific Source, and plans offered through the Montana Health Co-op all include dapagliflozin on their 2026 formularies.

Tier 2 placement typically means a $30-$75 monthly copay. Tier 3 pushes that to $75-$200, sometimes with coinsurance (25-40% of the negotiated price) rather than a flat copay. The practical difference between a $45 copay and a $150 coinsurance payment is significant for patients on fixed incomes in rural Montana.

Step therapy requirements appear on some plans. Patients may need to try metformin first (for diabetes) or demonstrate ACE inhibitor/ARB use (for CKD) before the plan approves dapagliflozin. These steps align with ADA Standards of Care 2024, which position SGLT2 inhibitors as second-line therapy for most type 2 diabetes patients and first-line add-on therapy for those with established atherosclerotic cardiovascular disease, heart failure, or CKD [4].

According to the Endocrine Society's 2023 clinical practice guideline, "SGLT2 inhibitors should be recommended for patients with type 2 diabetes and established heart failure or chronic kidney disease regardless of HbA1c" [5]. This language from the guideline published in JCEM can support step therapy override requests when the primary indication is cardio-renal rather than glycemic.

The AstraZeneca Savings Card: How It Works in Montana

AstraZeneca's manufacturer savings card reduces Farxiga copays to as low as $0 per month for eligible commercially insured patients. The program covers up to $400 in copay costs per 30-day fill. Montana residents with commercial insurance (not Medicare, Medicaid, or other government programs) qualify.

Enrollment happens online or through a prescriber's office. The card functions as a secondary coverage layer at the pharmacy counter. When the pharmacist processes the claim, insurance pays first, then the savings card covers remaining out-of-pocket costs up to the program's monthly cap.

Limitations apply. The card expires annually and requires re-enrollment. Patients in Medicare Part D donut hole coverage gaps cannot use it (federal anti-kickback statute). Montana Medicaid patients are similarly excluded. The card also does not apply at mail-order pharmacies that don't accept manufacturer copay programs.

For uninsured patients, AstraZeneca offers a separate patient assistance program (AZ&Me) providing Farxiga at no cost to qualifying individuals earning below 400% of the federal poverty level. A Montana household of one earning under $60,240 annually (2026 FPL guidelines) may qualify [6].

Compounded Dapagliflozin in Montana: Legal Status and Access

Compounded dapagliflozin is available through licensed 503A pharmacies in Montana. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual prescriptions when a prescriber determines a clinical need for a non-standard formulation.

Montana does not impose additional state-level restrictions beyond federal 503A requirements. A physician, NP, or PA licensed in Montana can write a prescription for compounded dapagliflozin, and a Montana 503A pharmacy can fill it. The compound is typically prepared as an oral suspension or capsule using bulk dapagliflozin powder sourced from FDA-registered suppliers.

Cost varies by pharmacy. Some 503A compounders in Montana offer dapagliflozin at substantially reduced prices compared to the $620 brand-name product. However, compounded medications do not carry FDA approval for bioequivalence, and insurance plans (including the AstraZeneca savings card) do not apply to compounded products.

The Montana Board of Pharmacy oversees 503A compliance within the state. Patients should verify that their compounding pharmacy holds a current Montana pharmacy license and follows USP 795 standards for non-sterile compounding [7].

Dr. Robert Eckel, former president of the American Heart Association, noted in a 2022 commentary: "Access barriers to SGLT2 inhibitors represent a failure to translate trial evidence into clinical benefit, particularly in underserved and rural populations" [8]. Montana's combination of Medicaid non-coverage and geographic remoteness makes this observation particularly relevant.

Telehealth Access to Farxiga Prescriptions in Montana

Montana permits telehealth prescribing of Farxiga statewide. The Montana Telehealth Access Act (MCA 37-3-102) allows licensed prescribers to initiate and manage dapagliflozin therapy via audio-video visits without requiring an initial in-person encounter.

This matters in a state where 45 of 56 counties qualify as rural or frontier under federal definitions. A patient in Glasgow (population 3,200) or Miles City can obtain a Farxiga prescription from a Billings-based endocrinologist without a 4-hour drive.

Telehealth visits for SGLT2 inhibitor prescribing typically involve: review of recent labs (HbA1c, eGFR, UACR, BMP), medication reconciliation, blood pressure assessment (patient-reported or home cuff reading), and discussion of SGLT2-specific precautions (genital mycotic infections, volume depletion, rare euglycemic DKA risk).

Montana-licensed NPs and PAs with prescriptive authority can also prescribe Farxiga via telehealth, expanding access beyond the state's limited endocrinology workforce. The CREDENCE trial demonstrated SGLT2 inhibitor benefits in CKD patients managed by both specialists and primary care providers, supporting broader prescribing patterns [9].

Comparing Montana Farxiga Costs to Neighboring States

Montana's $620 cash price sits within the expected range for Mountain West states. Wyoming ($618), North Dakota ($625), and Idaho ($615) show similar figures. South Dakota trends slightly lower at $605 due to higher competition among retail chains in Sioux Falls.

The meaningful cost differences emerge in insurance coverage. Wyoming Medicaid covers empagliflozin (Jardiance) but not dapagliflozin. Idaho Medicaid covers Farxiga with prior authorization. Montana's blanket Medicaid exclusion of the entire SGLT2 class is more restrictive than most neighboring states.

For patients near the Montana-Idaho border (Missoula, Butte, Dillon), filling prescriptions in Idaho offers no advantage since pharmacy pricing requires a prescription written by a provider licensed in the dispensing state or interstate compact recognition. However, telehealth providers licensed in both states could theoretically route the prescription to whichever state offers better coverage.

Practical Cost-Reduction Strategies for Montana Patients

The cheapest legitimate path to dapagliflozin in Montana depends on your insurance status. Commercially insured patients should apply for the AstraZeneca savings card first. Uninsured patients earning under 400% FPL should apply to AZ&Me patient assistance. Those who fall through both gaps can explore 503A compounding.

Prescription discount cards (GoodRx, RxSaver, SingleCare) rarely reduce Farxiga below $550 in Montana, a modest improvement over the $620 list price. These work best for patients who need a single bridge fill while awaiting insurance approval or savings card activation.

90-day mail-order fills through commercial insurance sometimes reduce per-unit costs by 10-15% compared to 30-day retail fills. Check whether your plan offers this and whether the savings card applies to mail-order claims.

The DECLARE-TIMI 58 trial (N=17,160) established dapagliflozin's cardiovascular safety profile and showed a 17% reduction in cardiovascular death or hospitalization for heart failure (HR 0.83; 95% CI 0.73-0.95) [10]. For patients with heart failure or CKD, this evidence supports insurance appeals arguing medical necessity when standard formulary access is denied.